Anthony R. Mato
Experienced in WT1-Related Wilms Tumor Syndromes

Dr. Anthony R. Mato

Oncology | Hematology
Cayuga Medical Center At Ithaca
101 Dates Dr, 
Ithaca, NY 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth

Experienced in WT1-Related Wilms Tumor Syndromes
Cayuga Medical Center At Ithaca
101 Dates Dr, 
Ithaca, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Anthony Mato is an Oncologist and a Hematologist in Ithaca, New York. Dr. Mato is rated as an Experienced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), Leukemia, Bone Marrow Transplant, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 175 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Hematology
Licenses
Internal Medicine in NY
Hospital Affiliations
Arnot Ogden Medical Center
Schuyler Hospital
Cayuga Medical Center At Ithaca
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

CAYUGA MEDICAL CENTER AT ITHACA
101 Dates Dr, Ithaca, NY 14850
Call: 607-274-4443
Other Locations
ARNOT OGDEN MEDICAL CENTER
600 Roe Ave, Elmira, NY 14905
Call: 607-737-4100

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


9 Clinical Trials

Veneto-STOP Study: Sequential Assessment of Minimal Residual Disease by Next Generation Sequencing to Optimize Outcomes and Minimize Exposure in Venetoclax-Treated CLL/SLL Patients
Veneto-STOP Study: Sequential Assessment of Minimal Residual Disease by Next Generation Sequencing to Optimize Outcomes and Minimize Exposure in Venetoclax-Treated CLL/SLL Patients
Enrollment Status: Recruiting
Publish Date: November 19, 2025
Intervention Type: Drug
Study Drugs: Venetoclax, Venetoclax+anti CD20 monoclonal antibody
Study Phase: Phase 2
A Phase II: Venetoclax-Based Therapy for the Treatment of Fit Patients With Chronic Lymphocytic Leukemia (CLL) in the Front-Line Setting
A Phase II: Venetoclax-Based Therapy for the Treatment of Fit Patients With Chronic Lymphocytic Leukemia (CLL) in the Front-Line Setting
Enrollment Status: Active_not_recruiting
Publish Date: October 14, 2025
Intervention Type: Drug
Study Drugs: Obinutuzumab, Venetoclax
Study Phase: Phase 2
A Phase 1/2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)
A Phase 1/2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)
Enrollment Status: Active_not_recruiting
Publish Date: September 25, 2025
Intervention Type: Drug
Study Drugs: LOXO-305, Rituximab
Study Phase: Phase 1/Phase 2
A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322)
A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322)
Enrollment Status: Active_not_recruiting
Publish Date: September 02, 2025
Intervention Type: Drug
Study Drugs: Pirtobrutinib, Venetoclax, Rituximab
Study Phase: Phase 3
A Phase 2 Time Limited Approach Based on Depth of Response to Front-Line Acalabrutinib in Combination With Obinutuzumab for CLL/SLL Patients Who Achieve Complete Remission or Partial Remission With Undetectable Minimal Residual Disease
A Phase 2 Time Limited Approach Based on Depth of Response to Front-Line Acalabrutinib in Combination With Obinutuzumab for CLL/SLL Patients Who Achieve Complete Remission or Partial Remission With Undetectable Minimal Residual Disease
Enrollment Status: Active_not_recruiting
Publish Date: August 27, 2025
Intervention Type: Drug
Study Drugs: Acalabrutinib, Obinutuzumab
Study Phase: Phase 2
Phase II Expansion Cohorts Studies of a Novel Triple Combination Therapy, DTRM-555, in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Relapsed/Refractory Non-Hodgkin's Lymphomas
Phase II Expansion Cohorts Studies of a Novel Triple Combination Therapy, DTRM-555, in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Relapsed/Refractory Non-Hodgkin's Lymphomas
Enrollment Status: Terminated
Publish Date: January 08, 2025
Intervention Type: Drug
Study Drug: Everolimus
Study Phase: Phase 2
Phase II Clinical Protocol for the Treatment of Patients With Previously Untreated CLL With Four or Six Cycles of Fludarabine and Cyclophosphamide With Rituximab (FCR) Plus Lenalidomide Followed by Lenalidomide Consolidation/ Maintenance
Phase II Clinical Protocol for the Treatment of Patients With Previously Untreated CLL With Four or Six Cycles of Fludarabine and Cyclophosphamide With Rituximab (FCR) Plus Lenalidomide Followed by Lenalidomide Consolidation/ Maintenance
Enrollment Status: Completed
Publish Date: October 10, 2022
Intervention Type: Drug
Study Drugs: Fludarabine, Cyclophosphamide, Rituximab, Lenalidomide
Study Phase: Phase 2
A Phase Ia/Ib Study of a Novel BTK Inhibitor, DTRMWXHS-12, and Combination Products, DTRM-505 and DTRM-555, in Patients With Chronic Lymphocytic Leukemia or Other B-cell Lymphomas
A Phase Ia/Ib Study of a Novel BTK Inhibitor, DTRMWXHS-12, and Combination Products, DTRM-505 and DTRM-555, in Patients With Chronic Lymphocytic Leukemia or Other B-cell Lymphomas
Enrollment Status: Completed
Publish Date: November 27, 2020
Intervention Type: Drug
Study Phase: Phase 1
Clonal Evolution of B Cells in High-risk Chronic Lymphocytic Leukemia Patients After Idelalisib-rituximab Treatment
Clonal Evolution of B Cells in High-risk Chronic Lymphocytic Leukemia Patients After Idelalisib-rituximab Treatment
Enrollment Status: Withdrawn
Publish Date: April 16, 2019
Intervention Type: Other
View 8 Less Clinical Trials

175 Total Publications

Protein Profiles Predict Treatment Responses to the PI3K Inhibitor Umbralisib in Patients with Chronic Lymphocytic Leukemia.
Protein Profiles Predict Treatment Responses to the PI3K Inhibitor Umbralisib in Patients with Chronic Lymphocytic Leukemia.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: September 04, 2024
View All 175 Publications
Similar Doctors
Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Alina Basnet
Hematology | Oncology
Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Alina Basnet
Hematology | Oncology

Guthrie Medical Group PC

34 W Main St, 
Cortland, NY 
 (18.5 miles away)
607-756-3130
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Alina Basnet is a Hematologist and an Oncologist in Cortland, New York. Dr. Basnet is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are Lung Cancer, Small Cell Lung Cancer (SCLC), Urothelial Cancer, Pleuropulmonary Blastoma, and Bone Marrow Aspiration. Dr. Basnet is currently accepting new patients.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Shilpa Sambidi
Hematology Oncology | Hematology | Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Shilpa Sambidi
Hematology Oncology | Hematology | Oncology

United Health Services Hospitals, Inc.

33 -57 Harrison St, 
Johnson City, NY 
 (38.4 miles away)
607-763-6101
Languages Spoken:
English
See accepted insurances

Shilpa Sambidi is a Hematologist Oncology specialist and a Hematologist in Johnson City, New York. Dr. Sambidi is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are Severe Congenital Neutropenia, Paget Disease of the Breast, Chronic Familial Neutropenia, Agranulocytosis, and Bone Marrow Aspiration.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Sam Benjamin
Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Sam Benjamin
Oncology

Department Of Medicine Medical Serv Grp At Suny Hlth Sci Ctr Syr In

750 E Adams St, 
Syracuse, NY 
 (44.4 miles away)
315-464-4457
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Sam Benjamin is an Oncologist in Syracuse, New York. Dr. Benjamin is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Angiosarcoma, Choriocarcinoma, Paget Disease of the Breast, and Breast Cancer.

VIEW MORE WT1-RELATED WILMS TUMOR SYNDROMES DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mato's expertise for a condition
ConditionClose
  • Elite
  • Chronic B-Cell Leukemia (CBCL)
    Dr. Mato is
    Elite
    . Learn about Chronic B-Cell Leukemia (CBCL).
    See more Chronic B-Cell Leukemia (CBCL) experts
  • Chronic Lymphocytic Leukemia (CLL)
    Dr. Mato is
    Elite
    . Learn about Chronic Lymphocytic Leukemia (CLL).
    See more Chronic Lymphocytic Leukemia (CLL) experts
  • Leukemia
    Dr. Mato is
    Elite
    . Learn about Leukemia.
    See more Leukemia experts
  • Non-Hodgkin Lymphoma
    Dr. Mato is
    Elite
    . Learn about Non-Hodgkin Lymphoma.
    See more Non-Hodgkin Lymphoma experts
  • Small Lymphocytic Lymphoma (SLL)
    Dr. Mato is
    Elite
    . Learn about Small Lymphocytic Lymphoma (SLL).
    See more Small Lymphocytic Lymphoma (SLL) experts
  • Distinguished
  • B-Cell Lymphoma
    Dr. Mato is
    Distinguished
    . Learn about B-Cell Lymphoma.
    See more B-Cell Lymphoma experts
  • Chronic Familial Neutropenia
    Dr. Mato is
    Distinguished
    . Learn about Chronic Familial Neutropenia.
    See more Chronic Familial Neutropenia experts
  • Gastric Lymphoma
    Dr. Mato is
    Distinguished
    . Learn about Gastric Lymphoma.
    See more Gastric Lymphoma experts
  • Mantle Cell Lymphoma (MCL)
    Dr. Mato is
    Distinguished
    . Learn about Mantle Cell Lymphoma (MCL).
    See more Mantle Cell Lymphoma (MCL) experts
  • Richter Syndrome
    Dr. Mato is
    Distinguished
    . Learn about Richter Syndrome.
    See more Richter Syndrome experts
  • Advanced
  • Agranulocytosis
    Dr. Mato is
    Advanced
    . Learn about Agranulocytosis.
    See more Agranulocytosis experts
  • Bone Marrow Transplant
    Dr. Mato is
    Advanced
    . Learn about Bone Marrow Transplant.
    See more Bone Marrow Transplant experts
  • Childhood Acute Myeloid Leukemia
    Dr. Mato is
    Advanced
    . Learn about Childhood Acute Myeloid Leukemia.
    See more Childhood Acute Myeloid Leukemia experts
  • Classical Hodgkin Lymphoma
    Dr. Mato is
    Advanced
    . Learn about Classical Hodgkin Lymphoma.
    See more Classical Hodgkin Lymphoma experts
  • Diffuse Large B-Cell Lymphoma (DLBCL)
    Dr. Mato is
    Advanced
    . Learn about Diffuse Large B-Cell Lymphoma (DLBCL).
    See more Diffuse Large B-Cell Lymphoma (DLBCL) experts
  • Febrile Neutropenia
    Dr. Mato is
    Advanced
    . Learn about Febrile Neutropenia.
    See more Febrile Neutropenia experts
View All 12 Advanced Conditions
  • Experienced
  • Acute Lymphoblastic Leukemia (ALL)
    Dr. Mato is
    Experienced
    . Learn about Acute Lymphoblastic Leukemia (ALL).
    See more Acute Lymphoblastic Leukemia (ALL) experts
  • Acute Monoblastic Leukemia (AmoL)
    Dr. Mato is
    Experienced
    . Learn about Acute Monoblastic Leukemia (AmoL).
    See more Acute Monoblastic Leukemia (AmoL) experts
  • Acute Myeloblastic Leukemia with Maturation
    Dr. Mato is
    Experienced
    . Learn about Acute Myeloblastic Leukemia with Maturation.
    See more Acute Myeloblastic Leukemia with Maturation experts
  • Acute Myeloblastic Leukemia without Maturation
    Dr. Mato is
    Experienced
    . Learn about Acute Myeloblastic Leukemia without Maturation.
    See more Acute Myeloblastic Leukemia without Maturation experts
  • Acute Myeloid Leukemia (AML)
    Dr. Mato is
    Experienced
    . Learn about Acute Myeloid Leukemia (AML).
    See more Acute Myeloid Leukemia (AML) experts
  • Acute Myelomonocytic Leukemia
    Dr. Mato is
    Experienced
    . Learn about Acute Myelomonocytic Leukemia.
    See more Acute Myelomonocytic Leukemia experts
View All 72 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved